Clinical Trial Update: A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating JNJ-54861911 on amyloid-beta processing in cerebrospinal fluid and plasma in prodromal Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• JNJ-54861911

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED